Multiple Myeloma (Kahler Disease) - Pipeline Review, H2 2016

 

Rating

4.8 Star Rating for report Multiple Myeloma (Kahler Disease) - Pipeline Review, H2 2016
4.8 / 5 stars rating
Pages: 1093
Price: $2500.00

Some of our Clients

Some Research and Expert Clients

Abstract

 
Multiple myeloma is a type of cancer that is caused by malignant plasma cells that proliferate in the bone marrow and produce abnormally high amounts of a special protein. The exact cause of multiple myeloma is not clear. Multiple myeloma mainly affects older adults. Symptoms include anemia, bleeding, nerve damage, skin lesions, bone tenderness or pain and kidney failure. Treatment includes chemotherapy, radiation, immunosuppression, and surgery.  

Description

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Multiple Myeloma (Kahler Disease) - Pipeline Review, H2 2016, provides an overview of the Multiple Myeloma (Kahler Disease) (Oncology) pipeline landscape.

Multiple myeloma is a type of cancer that is caused by malignant plasma cells that proliferate in the bone marrow and produce abnormally high amounts of a special protein. The exact cause of multiple myeloma is not clear. Multiple myeloma mainly affects older adults. Symptoms include anemia, bleeding, nerve damage, skin lesions, bone tenderness or pain and kidney failure. Treatment includes chemotherapy, radiation, immunosuppression, and surgery.
 

Similar Reports

Other reports that may be of interest...

Report... 05ID-GBIHC429MRFrontier Pharma: Melanoma Therapeutics - Cytokine and Multiple T...Jan 2017
Report... 05IB-GMDHC8848IDBColon Cancer - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8854IDBLiver Cancer - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8858IDBGlioblastoma Multiforme (GBM) - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8917IDBHigh-Grade Glioma - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8891IDBWilms' Tumor (Nephroblastoma) - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8896IDBMerkel Cell Carcinoma - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8908IDBRecurrent Malignant Glioma - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8909IDBMetastatic Uveal Melanoma - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8862IDBPancreatic Cancer - Pipeline Review, H2 2016Dec 2016

Report Source Information

Supplied by: Research and Experts 
Date Published: 2016-12-21 

Report: Multiple Myeloma (Kahler Disease) - Pipeline Review, H2 2016

 

Contents

Table of Contents
Table of Contents 2
Introduction 9
Multiple Myeloma (Kahler Disease) Overview 10
Therapeutics Development 11
Multiple Myeloma (Kahler Disease) - Therapeutics under Development by Companies 13
Multiple Myeloma (Kahler Disease) - Therapeutics under Investigation by Universities/Institutes 27
Multiple Myeloma (Kahler Disease) - Pipeline Products Glance 29
Multiple Myeloma (Kahler Disease) - Products under Development by Companies 33
Multiple Myeloma (Kahler Disease) - Products under Investigation by Universities/Institutes 57
Multiple Myeloma (Kahler Disease) - Companies Involved in Therapeutics Development 60
Multiple Myeloma (Kahler Disease) - Therapeutics Assessment 208
Drug Profiles 261
Multiple Myeloma (Kahler Disease) - Dormant Projects 1022
Multiple Myeloma (Kahler Disease) - Discontinued Products 1048
Multiple Myeloma (Kahler Disease) - Product Development Milestones 1053
Appendix 1060
 

List of Tables

List of Tables
Number of Products under Development for Multiple Myeloma (Kahler Disease), H2 2016 43
Number of Products under Development for Multiple Myeloma (Kahler Disease) - Comparative Analysis, H2 2016 44
Number of Products under Development by Companies, H2 2016 46
Number of Products under Development by Companies, H2 2016 (Contd..1) 47
Number of Products under Development by Companies, H2 2016 (Contd..2) 48
Number of Products under Development by Companies, H2 2016 (Contd..3) 49
Number of Products under Development by Companies, H2 2016 (Contd..4) 50
Number of Products under Development by Companies, H2 2016 (Contd..5) 51
Number of Products under Development by Companies, H2 2016 (Contd..6) 52
Number of Products under Development by Companies, H2 2016 (Contd..7) 53
Number of Products under Development by Companies, H2 2016 (Contd..8) 54
Number of Products under Development by Companies, H2 2016 (Contd..9) 55
Number of Products under Development by Companies, H2 2016 (Contd..10) 56
Number of Products under Development by Companies, H2 2016 (Contd..11) 57
Number of Products under Development by Companies, H2 2016 (Contd..12) 58
Number of Products under Investigation by Universities/Institutes, H2 2016 59
Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 60
Comparative Analysis by Late Stage Development, H2 2016 61
Comparative Analysis by Clinical Stage Development, H2 2016 62
Comparative Analysis by Early Stage Development, H2 2016 63
Comparative Analysis by Unknown Stage Development, H2 2016 64
Products under Development by Companies, H2 2016 65
Products under Development by Companies, H2 2016 (Contd..1) 66
Products under Development by Companies, H2 2016 (Contd..2) 67
Products under Development by Companies, H2 2016 (Contd..3) 68
Products under Development by Companies, H2 2016 (Contd..4) 69
Products under Development by Companies, H2 2016 (Contd..5) 70
Products under Development by Companies, H2 2016 (Contd..6) 71
Products under Development by Companies, H2 2016 (Contd..7) 72
Products under Development by Companies, H2 2016 (Contd..8) 73
Products under Development by Companies, H2 2016 (Contd..9) 74
Products under Development by Companies, H2 2016 (Contd..10) 75
Products under Development by Companies, H2 2016 (Contd..11) 76
Products under Development by Companies, H2 2016 (Contd..12) 77
Products under Development by Companies, H2 2016 (Contd..13) 78
Products under Development by Companies, H2 2016 (Contd..14) 79
Products under Development by Companies, H2 2016 (Contd..15) 80
Products under Development by Companies, H2 2016 (Contd..16) 81
Products under Development by Companies, H2 2016 (Contd..17) 82
Products under Development by Companies, H2 2016 (Contd..18) 83
Products under Development by Companies, H2 2016 (Contd..19) 84
Products under Development by Companies, H2 2016 (Contd..20) 85
Products under Development by Companies, H2 2016 (Contd..21) 86
Products under Development by Companies, H2 2016 (Contd..22) 87
Products under Development by Companies, H2 2016 (Contd..23) 88
Products under Investigation by Universities/Institutes, H2 2016 89
Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 90
Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 91
Multiple Myeloma (Kahler Disease) - Pipeline by 4SC AG, H2 2016 92
Multiple Myeloma (Kahler Disease) - Pipeline by AB Science SA, H2 2016 93
Multiple Myeloma (Kahler Disease) - Pipeline by AbbVie Inc, H2 2016 94
Multiple Myeloma (Kahler Disease) - Pipeline by Ablynx NV, H2 2016 95
Multiple Myeloma (Kahler Disease) - Pipeline by Acceleron Pharma Inc, H2 2016 96
Multiple Myeloma (Kahler Disease) - Pipeline by Acetylon Pharmaceuticals Inc, H2 2016 97
Multiple Myeloma (Kahler Disease) - Pipeline by Actinium Pharmaceuticals Inc, H2 2016 98
Multiple Myeloma (Kahler Disease) - Pipeline by Active Biotech AB, H2 2016 99
Multiple Myeloma (Kahler Disease) - Pipeline by Adaptimmune Therapeutics Plc, H2 2016 100
Multiple Myeloma (Kahler Disease) - Pipeline by ADC Therapeutics Sarl, H2 2016 101
Multiple Myeloma (Kahler Disease) - Pipeline by Aduro BioTech Inc, H2 2016 102
Multiple Myeloma (Kahler Disease) - Pipeline by Aeglea BioTherapeutics Inc, H2 2016 103
Multiple Myeloma (Kahler Disease) - Pipeline by Affimed GmbH, H2 2016 104
Multiple Myeloma (Kahler Disease) - Pipeline by AIMM Therapeutics BV, H2 2016 105
Multiple Myeloma (Kahler Disease) - Pipeline by Alissa Pharma, H2 2016 106
Multiple Myeloma (Kahler Disease) - Pipeline by Altor BioScience Corp, H2 2016 107
Multiple Myeloma (Kahler Disease) - Pipeline by Amgen Inc, H2 2016 108
Multiple Myeloma (Kahler Disease) - Pipeline by Anthera Pharmaceuticals Inc, H2 2016 109
Multiple Myeloma (Kahler Disease) - Pipeline by APIM Therapeutics AS, H2 2016 110
Multiple Myeloma (Kahler Disease) - Pipeline by APO-T BV, H2 2016 111
Multiple Myeloma (Kahler Disease) - Pipeline by Arcarios BV, H2 2016 112
Multiple Myeloma (Kahler Disease) - Pipeline by Arno Therapeutics Inc, H2 2016 113
Multiple Myeloma (Kahler Disease) - Pipeline by Array BioPharma Inc, H2 2016 114
Multiple Myeloma (Kahler Disease) - Pipeline by Arvinas Inc, H2 2016 115
Multiple Myeloma (Kahler Disease) - Pipeline by Asana BioSciences LLC, H2 2016 116
Multiple Myeloma (Kahler Disease) - Pipeline by Astellas Pharma Inc, H2 2016 117
Multiple Myeloma (Kahler Disease) - Pipeline by Astex Pharmaceuticals Inc, H2 2016 118
Multiple Myeloma (Kahler Disease) - Pipeline by AstraZeneca Plc, H2 2016 119
Multiple Myeloma (Kahler Disease) - Pipeline by Atara Biotherapeutics Inc, H2 2016 120
Multiple Myeloma (Kahler Disease) - Pipeline by Aurigene Discovery Technologies Ltd, H2 2016 121
Multiple Myeloma (Kahler Disease) - Pipeline by Bayer AG, H2 2016 122
Multiple Myeloma (Kahler Disease) - Pipeline by Bellicum Pharmaceuticals Inc, H2 2016 123
Multiple Myeloma (Kahler Disease) - Pipeline by BeyondSpring Pharmaceuticals Inc, H2 2016 124
Multiple Myeloma (Kahler Disease) - Pipeline by Biotest AG, H2 2016 125
Multiple Myeloma (Kahler Disease) - Pipeline by bluebird bio Inc, H2 2016 126
Multiple Myeloma (Kahler Disease) - Pipeline by Boston Biomedical Inc, H2 2016 127
Multiple Myeloma (Kahler Disease) - Pipeline by Bristol-Myers Squibb Company, H2 2016 128
Multiple Myeloma (Kahler Disease) - Pipeline by Calithera Biosciences Inc, H2 2016 129
Multiple Myeloma (Kahler Disease) - Pipeline by Celgene Corp, H2 2016 130
Multiple Myeloma (Kahler Disease) - Pipeline by Cell Source Inc, H2 2016 131
Multiple Myeloma (Kahler Disease) - Pipeline by Cellectar Biosciences Inc, H2 2016 132
Multiple Myeloma (Kahler Disease) - Pipeline by Cellectis SA, H2 2016 133
Multiple Myeloma (Kahler Disease) - Pipeline by Cellerant Therapeutics Inc, H2 2016 134
Multiple Myeloma (Kahler Disease) - Pipeline by Celleron Therapeutics Ltd, H2 2016 135
Multiple Myeloma (Kahler Disease) - Pipeline by CellProtect Nordic Pharmaceuticals AB, H2 2016 136
Multiple Myeloma (Kahler Disease) - Pipeline by Celyad SA, H2 2016 137
Multiple Myeloma (Kahler Disease) - Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2016 138
Multiple Myeloma (Kahler Disease) - Pipeline by Chugai Pharmaceutical Co Ltd, H2 2016 139
Multiple Myeloma (Kahler Disease) - Pipeline by Cleave Biosciences Inc, H2 2016 140
Multiple Myeloma (Kahler Disease) - Pipeline by Constellation Pharmaceuticals Inc, H2 2016 141
Multiple Myeloma (Kahler Disease) - Pipeline by Curis Inc, H2 2016 142
Multiple Myeloma (Kahler Disease) - Pipeline by Cyclacel Pharmaceuticals Inc, H2 2016 143
Multiple Myeloma (Kahler Disease) - Pipeline by Daiichi Sankyo Company Ltd, H2 2016 144
Multiple Myeloma (Kahler Disease) - Pipeline by DC Prime BV, H2 2016 145
Multiple Myeloma (Kahler Disease) - Pipeline by Eli Lilly and Company, H2 2016 146
Multiple Myeloma (Kahler Disease) - Pipeline by Enceladus Pharmaceuticals BV, H2 2016 147
Multiple Myeloma (Kahler Disease) - Pipeline by Exelixis Inc, H2 2016 148
Multiple Myeloma (Kahler Disease) - Pipeline by F. Hoffmann-La Roche Ltd, H2 2016 149
Multiple Myeloma (Kahler Disease) - Pipeline by Five Prime Therapeutics Inc, H2 2016 150
Multiple Myeloma (Kahler Disease) - Pipeline by Gamida Cell Ltd, H2 2016 151
Multiple Myeloma (Kahler Disease) - Pipeline by Genenta Science srl, H2 2016 152
Multiple Myeloma (Kahler Disease) - Pipeline by GlaxoSmithKline Plc, H2 2016 153
Multiple Myeloma (Kahler Disease) - Pipeline by Glenmark Pharmaceuticals Ltd, H2 2016 154
Multiple Myeloma (Kahler Disease) - Pipeline by Gliknik Inc, H2 2016 155
Multiple Myeloma (Kahler Disease) - Pipeline by GlycoMimetics Inc, H2 2016 156
Multiple Myeloma (Kahler Disease) - Pipeline by GlyTR Therapeutics Inc, H2 2016 157
Multiple Myeloma (Kahler Disease) - Pipeline by GP Pharm SA, H2 2016 158
Multiple Myeloma (Kahler Disease) - Pipeline by Heidelberg Pharma GmbH, H2 2016 159
Multiple Myeloma (Kahler Disease) - Pipeline by Hutchison MediPharma Ltd, H2 2016 160
Multiple Myeloma (Kahler Disease) - Pipeline by IGF Oncology LLC, H2 2016 161
Multiple Myeloma (Kahler Disease) - Pipeline by ImmunGene Inc, H2 2016 162
Multiple Myeloma (Kahler Disease) - Pipeline by Immunomedics Inc, H2 2016 163
Multiple Myeloma (Kahler Disease) - Pipeline by Incyte Corp, H2 2016 164
Multiple Myeloma (Kahler Disease) - Pipeline by Inflection Biosciences Ltd, H2 2016 165
Multiple Myeloma (Kahler Disease) - Pipeline by Inventiva, H2 2016 166
Multiple Myeloma (Kahler Disease) - Pipeline by Jasco Pharmaceuticals LLC, H2 2016 167
Multiple Myeloma (Kahler Disease) - Pipeline by Johnson & Johnson, H2 2016 168
Multiple Myeloma (Kahler Disease) - Pipeline by Juno Therapeutics Inc, H2 2016 169
Multiple Myeloma (Kahler Disease) - Pipeline by JW Pharmaceutical Corp, H2 2016 170
Multiple Myeloma (Kahler Disease) - Pipeline by Kancera AB, H2 2016 171
Multiple Myeloma (Kahler Disease) - Pipeline by Karus Therapeutics Ltd, H2 2016 172
Multiple Myeloma (Kahler Disease) - Pipeline by Karyopharm Therapeutics Inc, H2 2016 173
Multiple Myeloma (Kahler Disease) - Pipeline by Kesios Therapeutics Ltd, H2 2016 174
Multiple Myeloma (Kahler Disease) - Pipeline by Kite Pharma Inc, H2 2016 175
Multiple Myeloma (Kahler Disease) - Pipeline by LG Life Science LTD, H2 2016 176
Multiple Myeloma (Kahler Disease) - Pipeline by MediGene AG, H2 2016 177
Multiple Myeloma (Kahler Disease) - Pipeline by MedImmune LLC, H2 2016 178
Multiple Myeloma (Kahler Disease) - Pipeline by Medivation Inc, H2 2016 179
Multiple Myeloma (Kahler Disease) - Pipeline by Merck & Co Inc, H2 2016 180
Multiple Myeloma (Kahler Disease) - Pipeline by Mesoblast Ltd, H2 2016 181
Multiple Myeloma (Kahler Disease) - Pipeline by Millennium Pharmaceuticals Inc, H2 2016 182
Multiple Myeloma (Kahler Disease) - Pipeline by MimiVax LLC, H2 2016 183
Multiple Myeloma (Kahler Disease) - Pipeline by Molecular Partners AG, H2 2016 184
Multiple Myeloma (Kahler Disease) - Pipeline by Molecular Templates Inc, H2 2016 185
Multiple Myeloma (Kahler Disease) - Pipeline by MolMed SpA, H2 2016 186
Multiple Myeloma (Kahler Disease) - Pipeline by MorphoSys AG, H2 2016 187
Multiple Myeloma (Kahler Disease) - Pipeline by Nippon Kayaku Co Ltd, H2 2016 188
Multiple Myeloma (Kahler Disease) - Pipeline by Nordic Nanovector ASA, H2 2016 189
Multiple Myeloma (Kahler Disease) - Pipeline by Novartis AG, H2 2016 190
Multiple Myeloma (Kahler Disease) - Pipeline by Noxxon Pharma AG, H2 2016 191
Multiple Myeloma (Kahler Disease) - Pipeline by Oncodesign SA, H2 2016 192
Multiple Myeloma (Kahler Disease) - Pipeline by Oncolytics Biotech Inc, H2 2016 193
Multiple Myeloma (Kahler Disease) - Pipeline by Onconova Therapeutics Inc, H2 2016 194
Multiple Myeloma (Kahler Disease) - Pipeline by OncoPep Inc, H2 2016 195
Multiple Myeloma (Kahler Disease) - Pipeline by Oncopeptides AB, H2 2016 196
Multiple Myeloma (Kahler Disease) - Pipeline by Ono Pharmaceutical Co Ltd, H2 2016 197
Multiple Myeloma (Kahler Disease) - Pipeline by OXIS International Inc, H2 2016 198
Multiple Myeloma (Kahler Disease) - Pipeline by Peptinov SAS, H2 2016 199
Multiple Myeloma (Kahler Disease) - Pipeline by Pfizer Inc, H2 2016 200
Multiple Myeloma (Kahler Disease) - Pipeline by Pharma Mar SA, H2 2016 201
Multiple Myeloma (Kahler Disease) - Pipeline by Phylogica Ltd, H2 2016 202
Multiple Myeloma (Kahler Disease) - Pipeline by Polyphor Ltd, H2 2016 203
Multiple Myeloma (Kahler Disease) - Pipeline by Prescient Therapeutics Ltd, H2 2016 204
Multiple Myeloma (Kahler Disease) - Pipeline by Progenra Inc, H2 2016 205
Multiple Myeloma (Kahler Disease) - Pipeline by Quimatryx SL, H2 2016 206
Multiple Myeloma (Kahler Disease) - Pipeline by RedHill Biopharma Ltd, H2 2016 207
Multiple Myeloma (Kahler Disease) - Pipeline by Rhizen Pharmaceuticals SA, H2 2016 208
Multiple Myeloma (Kahler Disease) - Pipeline by Sanofi, H2 2016 209
Multiple Myeloma (Kahler Disease) - Pipeline by Seattle Genetics Inc, H2 2016 210
Multiple Myeloma (Kahler Disease) - Pipeline by Sellas Inc, H2 2016 211
Multiple Myeloma (Kahler Disease) - Pipeline by Selvita SA, H2 2016 212
Multiple Myeloma (Kahler Disease) - Pipeline by Senhwa Biosciences Inc, H2 2016 213
Multiple Myeloma (Kahler Disease) - Pipeline by Sorrento Therapeutics Inc, H2 2016 214
Multiple Myeloma (Kahler Disease) - Pipeline by Spectrum Pharmaceuticals Inc, H2 2016 215
Multiple Myeloma (Kahler Disease) - Pipeline by Sphaera Pharma Pvt Ltd, H2 2016 216
Multiple Myeloma (Kahler Disease) - Pipeline by Stemline Therapeutics Inc, H2 2016 217
Multiple Myeloma (Kahler Disease) - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H2 2016 218
Multiple Myeloma (Kahler Disease) - Pipeline by Surface Oncology Inc, H2 2016 219
Multiple Myeloma (Kahler Disease) - Pipeline by Sutro Biopharma Inc, H2 2016 220
Multiple Myeloma (Kahler Disease) - Pipeline by Taiho Pharmaceutical Co Ltd, H2 2016 221
Multiple Myeloma (Kahler Disease) - Pipeline by TaiRx Inc, H2 2016 222
Multiple Myeloma (Kahler Disease) - Pipeline by Takeda Pharmaceutical Company Ltd, H2 2016 223
Multiple Myeloma (Kahler Disease) - Pipeline by Targazyme Inc, H2 2016 224
Multiple Myeloma (Kahler Disease) - Pipeline by TeneoBio Inc, H2 2016 225
Multiple Myeloma (Kahler Disease) - Pipeline by Terpenoid Therapeutics Inc, H2 2016 226
Multiple Myeloma (Kahler Disease) - Pipeline by Teva Pharmaceutical Industries Ltd, H2 2016 227
Multiple Myeloma (Kahler Disease) - Pipeline by Theravectys SA, H2 2016 228
Multiple Myeloma (Kahler Disease) - Pipeline by TRACON Pharmaceuticals Inc, H2 2016 229
Multiple Myeloma (Kahler Disease) - Pipeline by Tragara Pharmaceuticals Inc, H2 2016 230
Multiple Myeloma (Kahler Disease) - Pipeline by Transgene Biotek Ltd, H2 2016 231
Multiple Myeloma (Kahler Disease) - Pipeline by Trillium Therapeutics Inc, H2 2016 232
Multiple Myeloma (Kahler Disease) - Pipeline by Vaccibody AS, H2 2016 233
Multiple Myeloma (Kahler Disease) - Pipeline by Vaxil Bio Therapeutics Ltd, H2 2016 234
Multiple Myeloma (Kahler Disease) - Pipeline by Verastem Inc, H2 2016 235
Multiple Myeloma (Kahler Disease) - Pipeline by Vichem Chemie Research Ltd, H2 2016 236
Multiple Myeloma (Kahler Disease) - Pipeline by Vivolux AB, H2 2016 237
Multiple Myeloma (Kahler Disease) - Pipeline by Vyriad Inc, H2 2016 238
Multiple Myeloma (Kahler Disease) - Pipeline by XTL Biopharmaceuticals Ltd, H2 2016 239
Assessment by Monotherapy Products, H2 2016 240
Assessment by Combination Products, H2 2016 241
Number of Products by Stage and Target, H2 2016 243
Number of Products by Stage and Mechanism of Action, H2 2016 266
Number of Products by Stage and Route of Administration, H2 2016 290
Number of Products by Stage and Molecule Type, H2 2016 292
Multiple Myeloma (Kahler Disease) - Dormant Projects, H2 2016 1054
Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..1), H2 2016 1055
Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..2), H2 2016 1056
Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..3), H2 2016 1057
Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..4), H2 2016 1058
Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..5), H2 2016 1059
Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..6), H2 2016 1060
Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..7), H2 2016 1061
Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..8), H2 2016 1062
Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..9), H2 2016 1063
Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..10), H2 2016 1064
Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..11), H2 2016 1065
Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..12), H2 2016 1066
Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..13), H2 2016 1067
Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..14), H2 2016 1068
Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..15), H2 2016 1069
Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..16), H2 2016 1070
Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..17), H2 2016 1071
Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..18), H2 2016 1072
Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..19), H2 2016 1073
Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..20), H2 2016 1074
Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..21), H2 2016 1075
Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..22), H2 2016 1076
Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..23), H2 2016 1077
Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..24), H2 2016 1078
Multiple Myeloma (Kahler Disease) - Dormant Projects (Contd..25), H2 2016 1079
Multiple Myeloma (Kahler Disease) - Discontinued Products, H2 2016 1080
Multiple Myeloma (Kahler Disease) - Discontinued Products (Contd..1), H2 2016 1081
Multiple Myeloma (Kahler Disease) - Discontinued Products (Contd..2), H2 2016 1082
Multiple Myeloma (Kahler Disease) - Discontinued Products (Contd..3), H2 2016 1083
Multiple Myeloma (Kahler Disease) - Discontinued Products (Contd..4), H2 2016 1084
 

List of Figures

List of Figures
Number of Products under Development for Multiple Myeloma (Kahler Disease), H2 2016 43
Number of Products under Development for Multiple Myeloma (Kahler Disease) - Comparative Analysis, H2 2016 44
Number of Products under Development by Companies, H2 2016 45
Number of Products under Investigation by Universities/Institutes, H2 2016 59
Comparative Analysis by Late Stage Development, H2 2016 61
Comparative Analysis by Clinical Stage Development, H2 2016 62
Comparative Analysis by Early Stage Products, H2 2016 63
Assessment by Monotherapy Products, H2 2016 240
Assessment by Combination Products, H2 2016 241
Number of Products by Top 10 Targets, H2 2016 242
Number of Products by Stage and Top 10 Targets, H2 2016 242
Number of Products by Top 10 Mechanism of Actions, H2 2016 265
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 265
Number of Products by Top 10 Routes of Administration, H2 2016 289
Number of Products by Stage and Top 10 Routes of Administration, H2 2016 289
Number of Products by Top 10 Molecule Types, H2 2016 291
Number of Products by Stage and Top 10 Molecule Types, H2 2016 291
 

Scope


- The pipeline guide provides a snapshot of the global therapeutic landscape of Multiple Myeloma (Kahler Disease) (Oncology).
- The pipeline guide reviews pipeline therapeutics for Multiple Myeloma (Kahler Disease) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Multiple Myeloma (Kahler Disease) (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Multiple Myeloma (Kahler Disease) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Multiple Myeloma (Kahler Disease) (Oncology)

 

Highlights

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Multiple Myeloma (Kahler Disease) - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Multiple Myeloma (Kahler Disease) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Multiple Myeloma (Kahler Disease) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Multiple Myeloma (Kahler Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 11, 61, 60, 2, 114, 22 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 6, 8, 18 and 6 molecules, respectively.

Multiple Myeloma (Kahler Disease) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

 

Classification

Language Code: EN 
Region: Global 
Report Type: Market Report 
Industry: Life Sciences 
Sector: Oncology 
Pages: 1093 

Companies Featured

4SC AG AB Science SA AbbVie Inc Ablynx NV Acceleron Pharma Inc Acetylon Pharmaceuticals Inc Actinium Pharmaceuticals Inc Active Biotech AB Adaptimmune Therapeutics Plc ADC Therapeutics Sarl Aduro BioTech Inc Aeglea BioTherapeutics Inc Affimed GmbH AIMM Therapeutics BV Alissa Pharma Altor BioScience Corp Amgen Inc Anthera Pharmaceuticals Inc APIM Therapeutics AS APO-T BV Arcarios BV Arno Therapeutics Inc Array BioPharma Inc Arvinas Inc Asana BioSciences LLC Astellas Pharma Inc Astex Pharmaceuticals Inc AstraZeneca Plc Atara Biotherapeutics Inc Aurigene Discovery Technologies Ltd Bayer AG Bellicum Pharmaceuticals Inc BeyondSpring Pharmaceuticals Inc Biotest AG bluebird bio Inc Boston Biomedical Inc Bristol-Myers Squibb Company Calithera Biosciences Inc Celgene Corp Cell Source Inc Cellectar Biosciences Inc Cellectis SA Cellerant Therapeutics Inc Celleron Therapeutics Ltd CellProtect Nordic Pharmaceuticals AB Celyad SA Chong Kun Dang Pharmaceutical Corp Chugai Pharmaceutical Co Ltd Cleave Biosciences Inc Constellation Pharmaceuticals Inc Curis Inc Cyclacel Pharmaceuticals Inc Daiichi Sankyo Company Ltd DC Prime BV Eli Lilly and Company Enceladus Pharmaceuticals BV Exelixis Inc F. Hoffmann-La Roche Ltd Five Prime Therapeutics Inc Gamida Cell Ltd Genenta Science srl GlaxoSmithKline Plc Glenmark Pharmaceuticals Ltd Gliknik Inc GlycoMimetics Inc GlyTR Therapeutics Inc GP Pharm SA Heidelberg Pharma GmbH Hutchison MediPharma Ltd IGF Oncology LLC ImmunGene Inc Immunomedics Inc Incyte Corp Inflection Biosciences Ltd Inventiva Jasco Pharmaceuticals LLC Johnson & Johnson Juno Therapeutics Inc JW Pharmaceutical Corp Kancera AB Karus Therapeutics Ltd Karyopharm Therapeutics Inc Kesios Therapeutics Ltd Kite Pharma Inc LG Life Science LTD MediGene AG MedImmune LLC Medivation Inc Merck & Co Inc Mesoblast Ltd Millennium Pharmaceuticals Inc MimiVax LLC Molecular Partners AG Molecular Templates Inc MolMed SpA MorphoSys AG Nippon Kayaku Co Ltd Nordic Nanovector ASA Novartis AG Noxxon Pharma AG Oncodesign SA Oncolytics Biotech Inc Onconova Therapeutics Inc OncoPep Inc Oncopeptides AB Ono Pharmaceutical Co Ltd OXIS International Inc Peptinov SAS Pfizer Inc Pharma Mar SA Phylogica Ltd Polyphor Ltd Prescient Therapeutics Ltd Progenra Inc Quimatryx SL RedHill Biopharma Ltd Rhizen Pharmaceuticals SA Sanofi Seattle Genetics Inc Sellas Inc Selvita SA Senhwa Biosciences Inc Sorrento Therapeutics Inc Spectrum Pharmaceuticals Inc Sphaera Pharma Pvt Ltd Stemline Therapeutics Inc Sumitomo Dainippon Pharma Co Ltd Surface Oncology Inc Sutro Biopharma Inc Taiho Pharmaceutical Co Ltd TaiRx Inc Takeda Pharmaceutical Company Ltd Targazyme Inc TeneoBio Inc Terpenoid Therapeutics Inc Teva Pharmaceutical Industries Ltd Theravectys SA TRACON Pharmaceuticals Inc Tragara Pharmaceuticals Inc Transgene Biotek Ltd Trillium Therapeutics Inc Vaccibody AS Vaxil Bio Therapeutics Ltd Verastem Inc Vichem Chemie Research Ltd Vivolux AB Vyriad Inc XTL Biopharmaceuticals Ltd

 

Reasons to buy this report


- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Multiple Myeloma (Kahler Disease) (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Multiple Myeloma (Kahler Disease) (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
 

Similar Reports

Other reports that may be of interest...

Report... 05ID-GBIHC429MRFrontier Pharma: Melanoma Therapeutics - Cytokine and Multiple T...Jan 2017
Report... 05IB-GMDHC8848IDBColon Cancer - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8854IDBLiver Cancer - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8858IDBGlioblastoma Multiforme (GBM) - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8917IDBHigh-Grade Glioma - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8891IDBWilms' Tumor (Nephroblastoma) - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8896IDBMerkel Cell Carcinoma - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8908IDBRecurrent Malignant Glioma - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8909IDBMetastatic Uveal Melanoma - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8862IDBPancreatic Cancer - Pipeline Review, H2 2016Dec 2016

Multiple Myeloma (Kahler Disease) - Pipeline Review, H2 2016

Report 05IB-GMDHC8844IDB has a rating of 96 percent
Figure of merit assessment for report 05IB-GMDHC8844IDB

Relevance Rating

The Research and Experts relevance ranting consists of a set of figure of merit (FOM) values that are provided as an indication of the value of the report in the current economic environment.

These FOM values cannot take into account the reason for the clients interest in a report and therefore the client should view these FOM values only as a visual guide. The FOM scores are based on

market interest - how often the report is viewed or purchased,
elapsed time - time since the report was published,
report detail - amount of detail in the report (pages, figures, images, comments etc.) and
price - the price of the report.


Regional Information

Taxonomy

Branch ID: 1591

Taxonomy Location

The taxonomy on the left shows the ancestors of the Global node. This provides an insight into parent categories that may provide reports or articles that may compliment this report. The number in brackets after the node name indicates the number of reports that Research and Experts currently have in the parent category.

Clicking on a parent category will present the list of reports in the parent node in a separate window.

Global

The global economy is the economy of all the world's countries. The total world population now stands at over 7 billion and the global unemployment rate is 9% with approximately half the world's population paid less than $2 a day. 

The global economy is picking up again after five years of uncertaintity and slow economic growth. The IMF is predicting global growth of 3.7% in 2014 rising to 3.9% in 2015. However, much uncertainity remains. Low inflation in developed economies means that these economies take longer to deal with debt burdens and are at increases risk of deflation. 

The second half of 2013 saw growth in the US and European economies (particularly UK, Germany and France).  

Growth in the US has been helped by cheaper energy from fracking , renewables and more oil and gas exploration. This cheaper energy is bring manufacturing jobs back to the US and helping to boost domestic demand. Recent winter weather conditions have hampered growth in the construction sector and have slowed demand in the construction equipment sector which saw exports drop by 25% in 2013. Growth should pick up in this sector with continued federal investment in infrastructure, new residential house builds and refurbishment and the energy boom.

In Europe growth is expected to be uneven with growth being slow in stressed economies such as Portugal and Greece but confidence picking up in UK, Ireland and even Spain showing some improvement.

Developing economies such as China and India will continue to have strong growth in 2014 and 2015. China has benefitted from increased investment with the Chinese govenment now focused on quality growth of 7.5% in 2014. India which is less reliant on exports expects growth of 5.4% in 2014 and 6.4% in 2015.

Much uncertainity still remains in the global economy with greater optimism needed to stabilise growth.

Links

World Bank

IMF (International Monetary Fund)

 

 

Zones

Regional zones

 

Country

Countries

 

Industry Sector Information

Taxonomy

Branch ID: 7174

Taxonomy Location

The taxonomy on the left shows the ancestors of the Oncology node. This provides an insight into parent categories that may provide reports or articles that may compliment this report. The number in brackets after the node name indicates the number of reports that Research and Experts currently have in the parent category.

Clicking on a parent category will present the list of reports in the parent node in a separate window.

Oncology

Oncology

 

Healthcare

The healthcare industry is changing rapidly due to changes in legislation (US Affordable Healthcare Act),  advances in IT and more pressures on governments and healthcare providers due to rising costs. 

According to a recent report by the OECD healthcare spending has fallen in one third of OECD member states due to the credit crunch and members are facing up to the challenge of providing greater care with fewer resources. Spending on healthcare has increased in Japan, Israel and Korea while it has dropped dramatically in Greece and Ireland.

Useful Links

World Health Organisation 

American Healthcare Association

The British Healthcare Business Intelligence Association

OECD, Health Policies and Data

Healthcare

Life Sciences

The Life Sciences industry includes biotechnology, healthcare, pharmaceuticals, medical devices and diagnostics. The industry is dominated by US companies requiring considerable investment in research and development to stay competitive.  While US companies dominate this space, competition is emerging from smaller companies in Europe and Asia. 

Companies trying to stay competitive or enter new markets in life sciences consult our reports. For example, Plimsoll, in their recent review of global antibiotic manufacturers have reviewed 150 of the largest manufacturers including analysis of  ANTIBIOTICE SA, BAYER HEALTHCARE MANUFACTURING SRL and CIPLA LTD. 

Our reports are a requirement for companies looking for the best competitive intelligence in the life sciences sector providing information on market size, rankings, best trading partners and financial analysis. 

Useful Links

Analytical Life Sciences and Diagnostics Association

German Life Sciences Association

 

Life Sciences

Industry

Industries

 

 

Buy: Multiple Myeloma (Kahler Disease) - Pipeline Review, H2 2016

 

Item Code: 05IB-GMDHC8844IDB

 
Licence: Single User
Price: $2500.00
 
VAT: 0.0% 
Total: $2500.00 

Feedback

Return to Research and Experts

Page created and rendered - Cache updated [1.43969s]

--